Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene,...

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Drug discovery Vol. 17; no. 4; p. 280
Main Authors:	Berry-Kravis, Elizabeth M, Lindemann, Lothar, Jønch, Aia E, Apostol, George, Bear, Mark F, Carpenter, Randall L, Crawley, Jacqueline N, Curie, Aurore, Des Portes, Vincent, Hossain, Farah, Gasparini, Fabrizio, Gomez-Mancilla, Baltazar, Hessl, David, Loth, Eva, Scharf, Sebastian H, Wang, Paul P, Von Raison, Florian, Hagerman, Randi, Spooren, Will, Jacquemont, Sébastien
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.04.2018
Subjects:	Animals Autism Biochemistry Clinical trials Clinical Trials as Topic Cognition & reasoning Cognitive ability Drug development Drug Development - methods Drug Evaluation, Preclinical Fragile X Syndrome - drug therapy Humans Intellectual disabilities Males Memory Mutation Neurodevelopmental disorders Neurodevelopmental Disorders - drug therapy Neurosciences Neurotransmitter Agents - pharmacology Neurotransmitter Agents - therapeutic use Pathophysiology Pediatrics Pharmaceutical industry Protein synthesis Proteins Randomized Controlled Trials as Topic
ISSN:	1474-1776, 1474-1784, 1474-1784
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!